Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.
Read original at benzingaStocks · News reference
8-K filing — DENTSPLY SIRONA Inc. (XRAY)
Filed: 2026-08-06 AccNo: 0000818479-26-000253 Size: 614 KB Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 8:14 PM
- Checked
- Aug 6, 2026, 8:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Dentsply Sirona's Wellspect HealthCare Announces U.S. Launch Of Surity Urinary Management System, Completing Surity External Catheter Portfolio
Read original at benzinga8-K/A filing — DENTSPLY SIRONA Inc. (XRAY)
Filed: 2026-08-07 AccNo: 0000818479-26-000263 Size: 615 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarDentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est
Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500 billion-$3.600 billion
Read original at benzinga